Qiang Wang

Dr. Qiang Wang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Experimental Cell Research
Verified
Journal Article
Closed access
XJXiaoli Ju
Xiaoli Ju
HZHeng Zhang
Heng Zhang
ZZZidi Zhou
Zidi Zhou
MCMiao Chen
Miao Chen
QWQiang Wang
Qiang Wang

1 January 2020
Verified
Journal Article
Closed access
XJXiaoli Ju
Xiaoli Ju
HZHeng Zhang
Heng Zhang
ZZZidi Zhou
Zidi Zhou
QWQiang Wang
Qiang Wang

1 June 2021 in Biochimie
Verified
Journal Article
Closed access
XJXiaoli Ju
Xiaoli Ju
ZYZhilong Yang
Zhilong Yang
HZHeng Zhang
Heng Zhang
QWQiang Wang
Qiang Wang

26 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
XJXiaoli Ju
Xiaoli Ju
RSRong Shen
Rong Shen
PHPan Huang
Pan Huang
JZJianhua Zhai
Jianhua Zhai
XQXiaobin Qian
Xiaobin Qian
MCMiao Chen
Miao Chen
Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer

10 December 2022 in Phytomedicine
Verified
Journal Article
Closed access
XJXiaoli Ju
Xiaoli Ju
HZHeng Zhang
Heng Zhang
JWJiayou Wang
Jiayou Wang
ZSZhonghe Sun
Zhonghe Sun
LGLanfang Guo
Lanfang Guo
QWQiang Wang
Qiang Wang

26 November 2021 in Toxicology Research
Verified
Journal Article
Closed access
QWQiang Wang
Qiang Wang
JWJing Wang
Jing Wang
JWJiayou Wang
Jiayou Wang
XJXiaoli Ju
Xiaoli Ju
HZHeng Zhang
Heng Zhang
Shikonin is one of the major bioactive components of Lithospermum erythrorhizon. It has a good killing effect in a variety of tumor cells. Its antitumor effect involves multiple targets and pathways and has received extensive attention and study in recent years. In this review, we systematically review recent progress in determining the antitumor mechanism of shikonin and its derivatives, specifically their induction of reactive oxygen species production, inhibition of EGFR and PI3K/AKT signaling pathway activation, inhibition of angiogenesis and induction of apoptosis and necroptosis. We also discuss the application of nanoparticles loaded with shikonin in the targeted therapy of various cancers. Finally, we suggest new strategies for the clinical application of shikonin and its derivatives.